Myriad Genetics First Quarter Revenues Up 22 Percent | GenomeWeb

NEW YORK, Nov. 7 – Myriad Genetics said Wednesday its fiscal first quarter revenues increased 22 percent to $13.2 million, compared with $10.8 million a year ago, boosted by strong sales of the company’s diagnostic products.

Myriad of Salt Lake City said that product revenues alone increased 81 percent in the quarter to $5.5 million. The company manufactures the BracAnalysis product for breast and ovarian cancer and the Colaris product for colon and uterine cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.